Pioneering Medical Company Completes Trial For Pruritus Treatment
Tharimmune Inc. Completes Phase 1 Clinical Trial for TH104, Moves to Phase 2 for Chronic Pruritus Treatment.
Disclaimer: This post includes affiliate links. If you purchase anything through these affiliated links, the author/website may earn a commission.
Tharimmune Inc., a pioneering biopharmaceutical company, has made a significant stride in the field of drug delivery and chronic pruritus treatment. The company recently announced the completion of its Phase 1 clinical trial with TH104, a proprietary transmucosal buccal film embedded with the approved, active compound nalmefene.
TH104 adheres inside the mouth on the cheek and biodegrades within minutes, offering a promising alternative to traditional drug delivery methods. The Phase 1 clinical trial compared oral transmucosal delivery of TH104 to the injectable reference approved drug.
The Phase 1 trial results demonstrated a positive safety and tolerability profile for TH104. The side effects noted were mild and self-resolving, aligning with previous studies. These outcomes pave the way for the next phase of clinical trials, bringing Tharimmune one step closer to providing an innovative solution for chronic pruritus patients.
Tharimmune Fully Funded into 2025
Amidst this progress, Tharimmune has ensured its financial stability moving forward. The company is fully funded into 2025, allowing it to continue its research and development efforts without interruption.
The successful completion of Phase 1 also sets the groundwork for the company's upcoming Phase 2 study. The Phase 2 trial will target moderate-to-severe chronic pruritus in primary biliary cholangitis (PBC), a liver disease that can cause severe itching. The study is expected to initiate in 2024.
The Implications of TH104
The development of TH104 represents a significant advancement in the treatment of chronic pruritus, particularly for patients with PBC. Current treatments often involve oral medications or injections, which can be inconvenient or uncomfortable for patients.
By creating a transmucosal buccal film like TH104, Tharimmune offers an alternative delivery method that is quick, easy, and less invasive. If successful, this could revolutionize the way chronic pruritus is treated, improving the quality of life for many patients.
Conclusion
Tharimmune's progress in the development of TH104 is a promising step forward in the field of chronic pruritus treatment. As the company moves into Phase 2 of clinical trials, the potential impact of this innovative drug delivery system becomes increasingly evident. Patients, medical professionals, and investors alike will be watching Tharimmune's journey closely as they continue to innovate and push boundaries in biopharmaceutical research.
The information in this article is accurate as of the date of publication. Always refer to the most recent information from trusted sources. This article is not intended to provide medical advice, diagnosis, or treatment. The author and publisher disclaim any liability for any damages arising from the use, misuse, or non-use of the information provided.
This article follows NewsBreak's Contributor Code of Conduct and rules.
As an investor it's important to stay updated with major news. Get real-time stock market alerts and research by creating an account here.
Sources: